Inhibrx Biosciences Inc (INBX) AI Stock Analysis

• Market Cap: $211.64M
• Dividend Yield: N/A
• Average Volume (3M): 81.67K
• Price to Earnings (P/E): 0.1
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 156
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -2.80
• Shares Outstanding: 14,475,904
• 10 Day Avg. Volume: 63,757
• 30 Day Avg. Volume: 81,666
• PEG Ratio: -0.10
• Price to Book (P/B): 17.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.52
• Enterprise Value/Market Cap: 4.33
• Enterprise Value/Revenue: 229.86
• Enterprise Value/Gross Profit: -950.69
• Enterprise Value/Ebitda: 0.14
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: $15.00 ▲(2.74%Upside)

The primary concern is the financial performance, characterized by declining revenues, high leverage, and negative cash flows, which significantly impact the score. Technical analysis shows some positive momentum, but potential overbought conditions pose risks. Valuation metrics suggest low market expectations, contributing to a cautious outlook.

Positive Factors

Financial Position

Inhibrx is well capitalized with $196.3 million in cash, allowing continued development of its key treatments.

Treatment Effectiveness

The combination of ozekibart and FOLFIRI shows a promising 40% overall response rate (ORR) in patients with 2L+ CRC, leading to a 7.85-month median progression-free survival (mPFS).

Trial Results

The INBRX-106 Phase 1 trial in HNSCC patients showed a 50% overall response rate, including complete and partial responses.

Negative Factors

Adverse Effects

31% of patients experienced an increase in alanine aminotransferase, indicating potential safety issues.

Potential Limitations

The safety profile of the combination therapy may limit its use, especially given the grade 5 event possibly linked to FOLFIRI.

Safety Concerns

A patient passed away due to neutropenic sepsis, raising concerns about the safety profile of the treatment.

Inhibrx Biosciences Inc Business Overview & Revenue Model

Company Description

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

How the Company Makes Money

Inhibrx makes money primarily through the development and commercialization of its therapeutic candidates. The company's revenue streams include potential milestone payments and royalties from partnerships with larger pharmaceutical companies that license Inhibrx's proprietary therapies. Additionally, Inhibrx may receive funding through collaboration agreements, research grants, and potentially through the sale of developed drugs once they receive regulatory approval and enter the market. Key factors contributing to earnings include successful clinical trials, strategic partnerships, and the commercialization of its biologics.

Inhibrx Biosciences Inc Financial Statement Overview

Summary

Inhibrx Biosciences Inc shows significant financial challenges with declining revenues, negative EBIT and EBITDA margins, high leverage, and negative cash flows. These factors indicate operational inefficiencies and financial risk, although external financing supports liquidity temporarily.

Income Statement

Inhibrx Biosciences Inc has faced significant challenges in revenue generation, with a decline from previous years and a negative EBIT and EBITDA margin indicating operational inefficiencies. Although there is a notable spike in net income for 2024, this appears to be an anomaly and not reflective of consistent profitability. Overall, the company struggles with achieving a sustainable revenue growth trajectory.

Balance Sheet

The company has shown some improvement in stockholders' equity, yet it remains heavily leveraged with a debt-to-equity ratio indicating high financial risk. The equity ratio is low, suggesting that the company relies significantly on debt financing, which could be risky if revenue does not improve. The high liabilities relative to assets further highlight potential solvency concerns.

Cash Flow

Operating cash flows are consistently negative, reflecting ongoing operational challenges. The free cash flow position is also negative, indicating limited internal generation of cash for reinvestment or debt repayment. However, the company has managed to secure external financing, which has supported liquidity but raises concerns about long-term financial sustainability.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
200.00K	200.00K	1.80M	2.18M	7.13M	12.81M
	Gross Profit
-964.00K	-2.08M	609.00K	-668.00K	4.44M	-60.69M
	EBIT
-300.52M	-331.45M	-219.22M	-129.12M	-76.56M	-67.44M
	EBITDA
1.73B	1.70B	-206.69M	-125.82M	-76.56M	-67.44M
	Net Income Common Stockholders
1.72B	1.69B	-241.36M	-145.23M	-81.77M	-75.64M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
216.52M	152.60M	277.92M	273.87M	131.30M	128.66M
	Total Assets
242.64M	180.77M	307.89M	290.88M	150.45M	143.74M
	Total Debt
7.88M	8.05M	210.14M	202.07M	70.47M	37.45M
	Net Debt
-208.64M	-144.55M	-67.78M	-71.80M	-60.83M	-91.21M
	Total Liabilities
148.20M	47.18M	264.39M	232.82M	98.07M	68.27M
	Stockholders Equity
94.44M	133.58M	43.50M	58.06M	52.38M	75.47M
Cash Flow		Free Cash Flow
-168.75M	-197.01M	-197.90M	-115.99M	-81.19M	-49.33M
	Operating Cash Flow
-167.25M	-194.41M	-193.31M	-115.30M	-80.32M	-47.97M
	Investing Cash Flow
-1.50M	-2.60M	-4.59M	-686.00K	-809.00K	-1.36M
	Financing Cash Flow
132.79M	71.68M	201.96M	258.55M	83.77M	166.46M

Inhibrx Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Positive. The current price of 14.6 is above the 20-day moving average (MA) of 13.79, above the 50-day MA of 12.64, and above the 200-day MA of 14.11, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 64.13 is Neutral, neither overbought nor oversold. The STOCH value of 69.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBX.

Inhibrx Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	58 Neutral	$4.93B	18.68	-16.94%	9.98%	13.73%	-24.47%
MGX	51 Neutral	$53.83M	―	-31.93%	―	-4.22%	18.67%
INBX	48 Neutral	$211.64M	0.12	3250.55%	―	―	―
ANRO	42 Neutral	$62.54M	―	-38.04%	―	―	―
CTNM	39 Underperform	$110.99M	―	-91.32%	―	-100.00%	-244.85%
FBLG	38 Underperform	$30.50M	―	-559.73%	―	―	―
KYTX	36 Underperform	$136.14M	―	-49.72%	―	―	―

Inhibrx Biosciences Inc Corporate Events

Inhibrx Biosciences Concludes 2025 Annual Stockholders Meeting

Inhibrx Biosciences, Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025, in a virtual format. During the meeting, a quorum of approximately 79% of eligible shares was present. Key outcomes included the election of Jon Faiz Kayyem, Ph.D., and Kristiina Vuori, M.D., Ph.D., as Class I Directors to serve until the 2028 Annual Meeting, and the ratification of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025.

Inhibrx Biosciences Appoints New President Amid Leadership Changes

On April 1, 2025, Inhibrx Biosciences, Inc. announced the appointment of David J. Matly as President, effective immediately, while he continues his role as Chief Commercial and Business Development Officer. This strategic move is expected to leverage Matly’s extensive experience in commercial launch and business development, enhancing the company’s market position. Concurrently, Brendan P. Eckelman resigned as Chief Scientific Officer on March 31, 2025, to establish a new private biotechnology company, marking a significant shift in the company’s leadership dynamics.